We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
mRNA疫苗Moderna对抗流感在4万名参与者的试验中优于传统疫苗。了解这将如何改变市场以及FDA决定何时出台。
mRNA药物mRNA-4359联合Keytruda显示出83%的应答率和17%的完全缓解。即使是PD-L1阴性肿瘤也缩小了。了解现成疫苗如何教导免疫系统攻击癌症,无需个性化定制。